These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 23000087)

  • 1. CXCL8, an underestimated "bad guy" in prostate cancer.
    Culig Z
    Eur Urol; 2013 Aug; 64(2):189-90; discussion 190-2. PubMed ID: 23000087
    [No Abstract]   [Full Text] [Related]  

  • 2. Potentiation of inflammatory CXCL8 signalling sustains cell survival in PTEN-deficient prostate carcinoma.
    Maxwell PJ; Coulter J; Walker SM; McKechnie M; Neisen J; McCabe N; Kennedy RD; Salto-Tellez M; Albanese C; Waugh DJ
    Eur Urol; 2013 Aug; 64(2):177-88. PubMed ID: 22939387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostaglandin E2 affects the tumor immune response in prostatic carcinoma.
    Kaneti J; Thomson DM; Reid EC
    J Urol; 1981 Jul; 126(1):65-70. PubMed ID: 6166761
    [No Abstract]   [Full Text] [Related]  

  • 4. Gata3 antagonizes cancer progression in Pten-deficient prostates.
    Nguyen AH; Tremblay M; Haigh K; Koumakpayi IH; Paquet M; Pandolfi PP; Mes-Masson AM; Saad F; Haigh JJ; Bouchard M
    Hum Mol Genet; 2013 Jun; 22(12):2400-10. PubMed ID: 23428429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel PI3K inhibitor displays potent preclinical activity against an androgen-independent and PTEN-deficient prostate cancer model established from the cell line PC3.
    Shi M; Zhou X; Zhang Z; Wang M; Chen G; Han K; Cao B; Liu Z; Mao X
    Toxicol Lett; 2014 Aug; 228(3):133-9. PubMed ID: 24831963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon-γ and tumor necrosis factor-α sustain secretion of specific CXC chemokines in human thyrocytes: a first step toward a differentiation between autoimmune and tumor-related inflammation?
    Rotondi M; Coperchini F; Pignatti P; Sideri R; Groppelli G; Leporati P; La Manna L; Magri F; Mariotti S; Chiovato L
    J Clin Endocrinol Metab; 2013 Jan; 98(1):308-13. PubMed ID: 23118425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathology of carcinoma of the prostate.
    Mostofi FK; Davis CJ; Sesterhenn IA
    Cancer; 1992 Jul; 70(1 Suppl):235-53. PubMed ID: 1376194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NOTCH and PTEN in prostate cancer.
    Bertrand FE; McCubrey JA; Angus CW; Nutter JM; Sigounas G
    Adv Biol Regul; 2014 Sep; 56():51-65. PubMed ID: 24933481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Role of the markers PAP-PSA in the diagnosis of cancer of the prostate].
    Petrone U; Gaspari G; Marascia G; Magnocavallo N; Petrone D; Tucci C
    Minerva Urol Nefrol; 1990; 42(2):73-5. PubMed ID: 1697431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin 8 and the male genital tract.
    Lotti F; Maggi M
    J Reprod Immunol; 2013 Nov; 100(1):54-65. PubMed ID: 23611586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of the phosphatidylinositol 3'-kinase pathway promotes autocrine Fas-induced death of phosphatase and tensin homologue-deficient prostate cancer cells.
    Bertram J; Peacock JW; Tan C; Mui AL; Chung SW; Gleave ME; Dedhar S; Cox ME; Ong CJ
    Cancer Res; 2006 May; 66(9):4781-8. PubMed ID: 16651432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity.
    Toso A; Revandkar A; Di Mitri D; Guccini I; Proietti M; Sarti M; Pinton S; Zhang J; Kalathur M; Civenni G; Jarrossay D; Montani E; Marini C; Garcia-Escudero R; Scanziani E; Grassi F; Pandolfi PP; Catapano CV; Alimonti A
    Cell Rep; 2014 Oct; 9(1):75-89. PubMed ID: 25263564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inflammatory Cytokine Signaling during Development of Pancreatic and Prostate Cancers.
    Liou GY
    J Immunol Res; 2017; 2017():7979637. PubMed ID: 29379802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [How to limit the progression of PTEN-deficient prostatic tumors?].
    Grelet É; Parisotto M; Metzger D
    Med Sci (Paris); 2018 Nov; 34(11):904-906. PubMed ID: 30526823
    [No Abstract]   [Full Text] [Related]  

  • 15. Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells.
    Cao C; Subhawong T; Albert JM; Kim KW; Geng L; Sekhar KR; Gi YJ; Lu B
    Cancer Res; 2006 Oct; 66(20):10040-7. PubMed ID: 17047067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pten deficiency activates distinct downstream signaling pathways in a tissue-specific manner.
    Yoo LI; Liu DW; Le Vu S; Bronson RT; Wu H; Yuan J
    Cancer Res; 2006 Feb; 66(4):1929-39. PubMed ID: 16488991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gambogic Acid Induces Cell Apoptosis and Inhibits MAPK Pathway in PTEN
    Pan H; Lu LY; Wang XQ; Li BX; Kelly K; Lin HS
    Chin J Integr Med; 2018 Feb; 24(2):109-116. PubMed ID: 28578487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CXCL8 hyper-signaling in the aortic abdominal aneurysm.
    Kokje VBC; Gäbel G; Dalman RL; Koole D; Northoff BH; Holdt LM; Hamming JF; Lindeman JHN
    Cytokine; 2018 Aug; 108():96-104. PubMed ID: 29587155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2.
    Nowak DG; Cho H; Herzka T; Watrud K; DeMarco DV; Wang VM; Senturk S; Fellmann C; Ding D; Beinortas T; Kleinman D; Chen M; Sordella R; Wilkinson JE; Castillo-Martin M; Cordon-Cardo C; Robinson BD; Trotman LC
    Cancer Discov; 2015 Jun; 5(6):636-51. PubMed ID: 25829425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The CXCL8-CXCR1/2 pathways in cancer.
    Liu Q; Li A; Tian Y; Wu JD; Liu Y; Li T; Chen Y; Han X; Wu K
    Cytokine Growth Factor Rev; 2016 Oct; 31():61-71. PubMed ID: 27578214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.